Over $9 billion star drug Qilu is the first domestic product to be reported for production.

1.Over $9 billion star drug Qilu is the first domestic product to be reported for production. Qilu pharmaceutical obtained the acceptance of CDE for the listing application of Aflibercept intraocular injection solution submitted by new drug category 3.3, which is the first reported production of Aflibercept biological similar drug in China.

2.On May 11, the listing application of levosalbuterol hydrochloride atomized inhalation solution submitted by Hunan Warner Pharmaceutical Co., Ltd. with generic drug category 3 was accepted by CDE. Levosalbuterol is commonly used β 2 receptor agonists. According to the data of Intranet, the sales of terminal l-salbutamol Hydrochloride Aerosol Inhalation Solution in public medical institutions in China in 2021 was about 200 million yuan, with a year-on-year increase of more than 3209%.

3.Enoxaparin sodium injection ushered in the fifth evaluated enterprise. The approaching of centralized purchase has made players in the field of heparin restless. According to the data of Intranet, the sales of terminal heparin and low molecular weight heparin preparations in Chinese public medical institutions exceeded 12 billion yuan in 2021, with a year-on-year increase of 12.98%. Among the top 10 products, enoxaparin sodium injection continued to lead, and the sales of 9 products increased significantly. Among the five Heparin API preparation integration enterprises, Heprui, Jianyou shares and Changshan pharmaceutical led the Heparin business revenue in 2021, forming a tripartite situation.

4.The launching ceremony of Zhongshan drug import port and the first batch of drug import customs clearance was held at Zhongshan port Sinotrans Wharf in Zhongshan Torch Development Zone, Guangdong Province. The first batch of “cefotaxime sodium” and ” Zhupo powder for children” imported by Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. and Hong Kong Baohetang Pharmaceutical Co., Ltd. successfully completed customs clearance, becoming the first batch of imported drugs to be cleared at the port.

5.On May 25, aosaikang again submitted the application for the marketing of class 2.2 new drugs of dextrolanzoprazole for injection. Takeda pharmaceutical only has oral preparation of dextrolanzolanzole. In 2021, it sold more than 50.7 billion yen (about 400million US dollars) globally. At present, there is no import or domestic approval of related products of this variety in the domestic market.

6.On May 25, Zhejiang Puli Pharmaceutical Co., Ltd. submitted the clinical application for class 2.2 new drug of memantine hydrochloride granules. Memantine is a best-selling variety of anti dementia drugs for nervous system drugs. Currently, there are capsules, tablets and oral liquid agents in the market, and no granules have been approved for listing or import. Puli is the first enterprise to apply for clinical application for granules.

7.On May 27, Shandong new era Pharmaceutical Co., Ltd. submitted the listing application for four types of imitation of etoxaban toluenesulfonate tablets. At present, there is no domestic generic drug of this product in the market. Hainan Xiansheng Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. and Nanjing Hailing Pharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group have submitted for production, which are under review and approval, and the dispute over the first generic drug is becoming more and more fierce.  Edoxaban is a selective factor Xa inhibitor developed by the first Sankyo. It was first approved for venous thromboembolism in Japan in 2011, and then a number of new indications were approved. In 2021, the global sales reached 189.4 billion yen (about 1.5 billion US dollars).

JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of JinDun Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.